- About Us
- Phase I
- Phase II
- Data Services
- Core Laboratories
- Case Studies
MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
Status: Recruiting, Condition Summary: Alzheimer Disease
Status: Recruiting, Condition Summary: Alzheimer Disease
Researchers now will have access to genetic data linked to medical information on a diverse group of more than 78,000 people, enabling investigations into many diseases and conditions.
Evolution Scientific (ESi), a technical service provider to the pharmaceutical, biotech, medical device and other regulated industries, has joined SAFE-BioPharma Association, the nonprofit industry coalition responsible for the ongoing development and implementation of the SAFE-BioPharma digital identity and signature standard.
According to a new market report published by Transparency Market Research, the global pharmacovigilance market was valued at $2,147.3 million in 2012 and is estimated to reach a market worth $5,008.2 million in 2019, at a CAGR of 12.9% from 2013 to 2019.
Charles River Laboratories is the first CRO to join Exostar’s rapidly growing life sciences community, which currently includes numerous CROs among the more than 500 organizations and 10,000 individuals in almost 50 countries worldwide. The Exostar Life Sciences Identity Hub brings CROs, pharmaceutical manufacturers and academic institutions together to facilitate secure collaboration, reduce capital and operating expenditures and drive revenue by enhancing productivity and speeding time-to-market.
Cardialysis, an independent CRO, has selected AG Mednet, a quality compliance company, as preferred provider for image data submission and collection.
Salix Pharmaceuticals, a North Carolina-based developer and marketer of prescription pharmaceutical products and medical devices, and RedHill Biopharma, an emerging Israeli biopharmaceutical company, have entered into an exclusive agreement by which Salix has licensed the worldwide exclusive rights to RedHill's RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments.
BBK Worldwide, a provider of patient recruitment, has launched BIO Notifier Plus, which utilizes a global opt-in physician database, a proprietary rating and ranking system and in-country direct physician contact to bring specialists to clinical trials.
The Parkinson's Progression Markers Initiative (PPMI), a large-scale biomarker study sponsored by The Michael J. Fox Foundation for Parkinson's Research (MJFF), is expanding to study individuals with genetic mutations associated with Parkinson's disease (PD). Researchers hope that greater understanding of the biology and clinical features of these participants—people with or at risk to develop Parkinson's—will lead to therapeutics that would help all Parkinson's patients and ultimately provide strategies to prevent disease onset.
CluePoints, a provider of Risk-Based Monitoring (RBM) solutions for clinical trials, has announced three new appointments to its global team. John Colby and Elizabeth Polvent join the company's U.S business development team, fulfilling a key element in its strategy for growth, while CluePoints also welcomes Jean Stéphenne, president of the board of directors of GlaxoSmithKline Biologicals, as a member of its board.
Sinovac Biotech, a provider of biopharmaceutical products in China, has announced that Phase III clinical trial results for its proprietary Enterovirus 71 (EV71) vaccine have been published online in the February 27 issue of TheNew England Journal of Medicine (NEJM). The clinical results showed the efficacy of the vaccine against EV71-associated hand, foot and mouth disease (HFMD), or herpangina, was 94.8% among infants and young children and an anti-EV71 neutralizing antibody titer of 1:16 was associated with protection against EV71 associated HFMD or herpangina. As outlined in the NEJM article, Sinovac's vaccine also demonstrated a 100% efficacy rate against EV71-associated hospitalization and against HFMD with neurologic complications, the main cause of fatalities.
CRO Venn Life Sciences has announced the acquisition of the intellectual property rights for Labskin, SYN1113 and related equipment of Evocutis, for $287,000 in new ordinary shares in Venn.
Novartis has announced additional steps to extend its presence in clinical trial data transparency. Since 2005, and before requirements were in place, Novartis has been voluntarily disclosing summaries of Clinical Study Reports of its innovative medicines on its own web site (www.novctrd.com). In addition, the company is committed to enhancing Clinical Study Report summaries for all new pivotal studies to include easy to understand consumer language summaries and additional interpretation of data as of the end of 2014.
Bayer plans to acquire Dihon Pharmaceutical Group, a privately held pharmaceutical company based in Kunming Yunnan, China, specializing primarily in over-the-counter (OTC) and herbal traditional Chinese medicine (TCM) products.
According to the Press Information Bureau of the Indian government, the FDA and India’s Ministry of Health and Family Welfare have signed a Statement of Intent on Cooperation in the Field of Medical Products.
First quarter 2013 FAERS data files have been added.
Comunicado de la FDA sobre la seguridad de los medicamentos: La FDA advierte de posibles efectos adversos por exceder la dosis recomendada de productos de venta libre que contienen fosfato de sodio para el tratamiento del estreñimiento
La Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) advirtió que usar más de una dosis en 24 horas de medicamentos de venta libre (OTC por sus siglas en inglés) que contienen fosfato de sodio para tratar el estreñimiento, puede causar en ocasiones poco frecuente daño serio a los riñones y corazón, e incluso la muerte.